Multifocal IOLs as presbyopia treatment
Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.
Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.
Dr Thomas Neuhann of the Augenklinik am Marienplatz, Munich, Germany evaluated monocular implantation of a multifocal diffractive apodized IOL (SN60D3, AcrySof ReSTOR Natural; Alcon) as a rehabilitative treatment for emmetropic and presbyopic patients (n=24).
Six months after unilateral implantation, all patients were found to have bilateral uncorrected near vision of 20/30; 83% of patients recorded uncorrected distance vision of 20/20. Half of patients remained spectacle-dependent for intermediate vision. A questionnaire determined overall patient satisfaction of 79% for near, intermediate and distance vision. One patient requested IOL implantation in the second eye.
Dr Neuhann concluded that unilateral IOL implantation offers a viable treatment option for sufferers of emmetropia and presbyopia.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
